We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Generic Pharmaceutical Association (GPhA) issued a study July 31 that shows the long-term effect of allowing brand drug companies to launch an authorized generic during a generic firm’s 180-day exclusivity period will be decreased competition and reduced access to cheaper drugs.
Troubles continue for Neurocrine Biosciences in the wake of a regulatory delay of the insomnia drug indiplon as the company announced it is eliminating its sales staff.
Device and diagnostics makers can avoid being blamed for inflated healthcare costs by focusing on competitive strategies that add value to their products, experts say.
Based on encouraging clinical trial data, GlaxoSmithKline (GSK) will likely file for regulatory approval to market its pandemic bird flu vaccine within the next few months.
The Journal of the American Medical Association (JAMA) has published another correction in which they said the authors of an article did not disclose ties to the drug industry when they submitted their article manuscript.
A more efficient and accurate method of assessing biological reactions to chemical compounds will accelerate new drug development, according to a paper published online July 24 by the journal Proceedings of the National Academy of Sciences.
Novartis’ cancer drug Gleevec and other drugs in its class can put patients at risk of heart failure, according to a study published in the July 23 issue of Nature Medicine.
Encouraging data from clinical trials of GlaxoSmithKline’s (GSK’s) pandemic bird flu vaccine have led the company to announce that it will likely file for regulatory approval to market the product in the next few months.
A more efficient and accurate method of assessing biological reactions to chemical compounds will hasten new drug development, according to a paper published online July 24 by the journal Proceedings of the National Academy of Sciences.